Phase II Randomized Study of Hypofractionated Versus Conventional Radiotherapy

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of Texas Southwestern Medical Center

About this trial

To compare the acute tolerance of highly conformal hypofractionated versus conventional radiotherapy.

Eligibility criteria

Qualifiers

Pathologically-proven diagnosis of squamous cell carcinoma in situ, squamous cell carcinoma, or squamous cell variants (sarcomatoid, verrucous, basaloid, and papillary subtypes) involving the glottic larynx.

Clinical stage 0-II (AJCC, 8th edition) with direct laryngoscopy showing no evidence of greater than stage II true glottic larynx cancer and PET/CT or CT neck showing no evidence of regional disease.

Minimum age is 18 years.

ECOG Performance Status 0-2

Disqualifiers

AJCC stage III or stage IV larynx cancer

Involvement of the arytenoid cartilage beyond the vocal process.

Prior chemotherapy for treatment of the targeted larynx lesion.

Synchronous primaries in the head and neck

Trial design

Treatments tested in this trial

  • LT-SABR
  • IMRT

Treatment groups

67 Participants
are divided into 2 treatment groups